fda glp-1 compounding crackdown news october 2025 is moving to restrict mass-marketed compounded products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified National Hispanic Medical Association |

2022;34(9):1234-1247.e9

Counterfeit drugs often lack efficacy, pose health hazards, and erode brand reputation for innovator companies

They make the category investable By standardizing CAC, retention, staffing, and fulfillment, they make it easier for growth funds to invest downstream

Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO) Kidney Int

There is a strong interest in developing obesity treatments based on glucagon-like peptide-1 (GLP-1) agonists, which have proved to limit morbidity and mortality in type 2 diabetes

Compounding pharmacies prioritize freshness and personalization over multi-year shelf stability